HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

HLS.TO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

HLS Therapeutics Inc.TSX: HLS.TO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of $3.27M rose 11.9% year over year, behind the +21.8% change in trailing-twelve-month EBITDA. Sequentially, it fell 43.6% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.

Context

  • EBITDA amounted to 31.9% of revenue in FY2025, up 1.5 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $20.39M (+13.1%) for the fiscal year ending Dec 2026, a step up from the +4.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.27M-43.6% QoQ
Last fiscal yearDec 2025
$18.02M+4.7% YoY
LTMMar 2026
$17.79M+21.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.9%-22.5%-34.4 pp
1 year+4.7%+13.1%+8.5 pp
3-year CAGR+0.0%+12.0%+12.0 pp
5-year CAGR+16.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
18.02M USD
Year-over-year change
+4.7%
4-year CAGR
-8.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How HLS.TO compares with its peers on the latest reported figures

  • HLS.TO's LTM Mar 2026 EBITDA of $17.79M is the 3rd highest of the 7 companies compared; the peer median is $1.82M.
  • Its year-over-year change of +21.8% is the 2nd highest of 7, against a peer median of -39.0%.
  • EBITDA amounts to 31.9% of revenue for HLS.TO, versus a peer median of 18.9%.
HLS.TO Competitors Peer median
EBITDA for HLS.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$2.05B -37.3%+3.4%18.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$652.2M +11.7%+11.1%20.9%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$17.79M +21.8%+0.0%31.9%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$5.45M +504.9%—6.3%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-$1.82M -156.1%+107.1%4.3%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$51.63M -40.6%—102.7%
NERVMinerva Neurosciences, Inc.LTM Jun 2026-$394.35M -3608.6%——
Peer median (excluding HLS.TO) $1.82M-39.0%+11.1%18.9%

Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.01M61.47M63.07M56.62M56.47M
Cost of Revenue3.97M4.98M7.62M9M32.46M
Gross Profit56.04M56.49M55.45M47.62M24.01M
Gross Margin93.4%91.9%87.9%84.1%42.5%
Research & Development00000
Selling, General & Admin32.06M35.58M28.29M26.93M22M
Operating Expenses62.32M69.98M55.45M55.31M28.19M
Depreciation & Amortization30.26M34.4M31.94M22.72M22.2M
EBITDA25.41M18M12.88M17.22M18.02M
EBITDA Margin42.3%29.3%20.4%30.4%31.9%
Operating Income(6.24M)(13.44M)(10.35M)(7.69M)(4.18M)
Operating Margin-10.4%-21.9%-16.4%-13.6%-7.4%
Interest Income44K57K350K319K108.87K
Interest Expense6.96M7.32M8.75M10.08M7.22M
Other Income / Expenses(5.52M)(10.23M)(17.45M)(7.9M)(8.92M)
Income Before Tax(11.81M)(23.72M)(27.8M)(15.58M)(13.1M)
Pre-Tax Margin-19.7%-38.6%-44.1%-27.5%-23.2%
Income Tax Expense1.31M(124K)(272K)4.07M(452.79K)
Net Income(13.12M)(23.6M)(27.53M)(19.66M)(12.65M)
Net Margin-21.9%-38.4%-43.6%-34.7%-22.4%
EPS (Basic)(0.41)(0.73)(0.85)(0.62)(0.40)
EPS (Diluted)(0.41)(0.73)(0.85)(0.62)(0.40)
Weighted Avg Shares32.18M32.33M32.26M31.84M31.53M
Weighted Avg Shares (Diluted)32.18M32.43M32.26M31.84M31.53M

HLS Therapeutics Inc.

TSX:HLS.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.